urapidil has been researched along with Prostatic Hyperplasia in 5 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two men with benign prostatic hyperplasia who were treated with a nonselective alpha 1-blocker (urapidil) were included." | 3.72 | Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome. ( Kumon, H; Nishiguchi, J; Nose, H; Ozawa, H; Watanabe, Y; Yokoyama, T, 2004) |
| "The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992) |
| " In summary, a daily dosage of 60 mg urapidil proved to be the most beneficial in the treatment of patients with BPH." | 2.67 | Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. ( Kageyama, S; Kawabe, K; Morita, T; Shimazaki, J; Tsuchida, S; Yasuda, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, T | 1 |
| Monden, K | 1 |
| Araki, M | 1 |
| Watanabe, Y | 1 |
| Yokoyama, T | 1 |
| Ozawa, H | 1 |
| Nishiguchi, J | 1 |
| Nose, H | 1 |
| Kumon, H | 1 |
| Takehara, Y | 1 |
| Igawa, K | 1 |
| Satoh, T | 1 |
| Yokozeki, H | 1 |
| Kawabe, K | 1 |
| Tsuchida, S | 1 |
| Shimazaki, J | 1 |
| Morita, T | 2 |
| Yasuda, K | 1 |
| Kageyama, S | 1 |
| Kondo, S | 1 |
2 trials available for urapidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos | 2013 |
Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Piperazines; Prospective Studies; P | 1993 |
3 other studies available for urapidil and Prostatic Hyperplasia
| Article | Year |
|---|---|
Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Piperazines; Predi | 2004 |
Psoriasiform eruption induced by alpha1-adrenergic blocker, urapidil.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Eruptions; Erythema; Humans; Male; Piperazines; Prostatic H | 2007 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla | 1992 |